Molecular epidemiology and resistance mechanisms of tigecycline-non-susceptible Acinetobacter baumannii isolated from a tertiary care hospital in Chongqing, China-Reference-Cited by-同舟云学术

Molecular epidemiology and resistance mechanisms of tigecycline-non-susceptible Acinetobacter baumannii isolated from a tertiary care hospital in Chongqing, China

Published:2024-04-15 Issue: Volume: Page:
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Liao Jiajia,Huang Jinzhu,Xia Peiwen,Yang Bingxue,Dang Zijun,Luo Shengli,Tang Shiyu,Li Yuqiong,Han Qi,Xia Yun^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10096-024-04832-9.pdf

Reference21 articles.

1. Novovic K, Jovcic B (2023) Colistin Resistance in Acinetobacter baumannii: Molecular mechanisms and Epidemiology. Antibiot (Basel) 12(3). https://doi.org/10.3390/antibiotics12030516

2. Zhang J, Xie J, Li H, Wang Z, Yin Y, Wang S, Chen H, Wang Q, Wang H (2022) Genomic and phenotypic evolution of Tigecycline-Resistant Acinetobacter baumannii in critically ill patients. Microbiol Spectr 10(1):e0159321. https://doi.org/10.1128/spectrum.01593-21

3. Visca P, Seifert H, Towner KJ (2011) Acinetobacter infection–an emerging threat to human health. IUBMB Life 63(12):1048–1054. https://doi.org/10.1002/iub.534

4. Paterson DL, Harris PN (2015) Editorial commentary: the new Acinetobacter equation: hypervirulence plus antibiotic resistance equals big trouble. Clin Infect Dis 61(2):155–156. https://doi.org/10.1093/cid/civ227

5. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z, Maleki F (2022) Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis 41(7):1003–1022. https://doi.org/10.1007/s10096-020-04121-1